Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2025-03-25
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well gallium-68 PSMA-11 PET/CT or PET/MRI works in finding
prostate cancer cells that have come back (recurrent) in patients with prostate cancer.
Gallium-68 PSMA-11 is a type of radioactive compound, called a radiotracer, which is injected
in the vein and can accumulate in tumor cells to generate a signal detected by PET/CT or
PET/MRI imaging. This may help researchers in finding recurrent prostate cancer cells in
patients with prostate cancer.